Swiss National Bank
CAPR icon

Swiss National Bank’s Capricor Therapeutics CAPR Stock Holding History

Swiss National Bank’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.24M Sell
92,900
-3,900
-4% -$118K ﹤0.01% 1891
2026
Q1 		$2.94M Buy
+96,800
New +$2.58M ﹤0.01% 1650
2025
Q3 		– Sell
-79,300
Closed -$787K – 2327
2025
Q2 		$787K Hold
79,300
– – ﹤0.01% 2229
2025
Q1 		$753K Buy
79,300
+11,900
+18% +$165K ﹤0.01% 2252
2024
Q4 		$930K Buy
+67,400
New +$1.18M ﹤0.01% 2229

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Swiss National Bank's CAPR Position: Q2 2026 in Review

Swiss National Bank reduced its Capricor Therapeutics (CAPR) stake by 4% in Q2 2026, selling an estimated $118K and leaving 92,900 shares worth $2.24M. The position accounts for ﹤0.01% of the portfolio, ranked #1891.

Swiss National Bank first reported a position in CAPR in Q4 2024 and has held it in 5 quarters since. The position peaked at $2.94M in Q1 2026. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Swiss National Bank held 92,900 shares of Capricor Therapeutics worth $2.24M as of Q2 2026.
  • Swiss National Bank sold 3,900 Capricor Therapeutics shares in Q2 2026, an estimated $118K.
  • Capricor Therapeutics made up ﹤0.01% of Swiss National Bank's portfolio in Q2 2026, its #1891 holding.
  • Swiss National Bank first reported a position in Capricor Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • Swiss National Bank's Capricor Therapeutics position peaked at $2.94M in Q1 2026.
  • 169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.